The ABPI is pleased to announce the appointment of Catherine Meaden as Head of Policy & Public Affairs. She will join the ABPI, which represents research-based pharmaceutical companies, in April 2012 and will report to Amanda Callaghan, Director of Corporate Affairs.
Catherine joins the ABPI from NHS Direct, where she spent three years as Associate Director of Marketing and Communications. She previously held communications roles at the NHS Confederation and Cancer Research UK.
Catherine will lead the ABPI’s communications to parliamentarians and other senior stakeholders around the pharmaceutical industry’s valued contribution to the UK economy and healthcare. As part of its public affairs work, the ABPI will continue to highlight the importance and value of innovation, particularly in relation to research and development; encourage greater uptake of and access to medicines; and work in partnership with government to ensure a fair price for medicines in the UK.
Amanda Callaghan, Director of Corporate Affairs for the ABPI said:
“We are delighted to have Catherine on board. Her appointment completes our new communications team, and reflects our commitment to represent our members’ interests successfully, particularly in the complex environment we face today.”
Commenting on her appointment, Catherine Meaden said:
“This is an exciting time to be joining the new ABPI team, and to be tackling some of the major issues facing not only our members, but government, the NHS and patients. I look forward to working closely with parliamentarians, stakeholders and patient research groups to ensure that this industry continues to be recognised for the value it brings to the economy and, most importantly, health outcomes in the UK.”
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: firstname.lastname@example.org
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.